What it sells
Programmable biology company for psychoactive effect design
Business model breakdown
Workflow: what inputs become what output?
Closed-loop platform (Osmanthus) maps molecular structure to first-person experience narratives to design psychoactive effects; clinical programs test fixed-dose combinations.
Economics: what it saves and how it charges
UnverifiedDrug-development company; no product revenue shown, value from clinical programs and IP (inferred).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.